Natural killer cells in psoriasis

Journal of Innate Immunity

Volumn 3, Issue 4, 2011, Pages 403-410

  Tobin, A M ^a   Lynch, L ^a   Kirby, B ^a   O'Farrelly, C ^b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Innate immunity; Natural killer cells; Psoriasis

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; GAMMA INTERFERON; HLA C ANTIGEN; HLA CW6 ANTIGEN; INFLIXIMAB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL5; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS1; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLELE; CELL FUNCTION; CELLULAR DISTRIBUTION; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INNATE IMMUNITY; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; REVIEW; SYSTEMIC THERAPY; TH1 CELL; TH17 CELL;

HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; PSORIASIS; SKIN;

EID: 80955180091     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000328011     Document Type: Review

References (71)

1. Christophers E: Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 15:20-23.
2. Griffiths CE, Barker JN: Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
3. Nickoloff BJ, Qin JZ, Nestle FO: Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 2007; 33: 45-56.
4. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, Su B, Nestle FO, Zal T, Mellman I, Schröder JM, Liu YJ, Gilliet M: Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564-569.
5. McFadden JP, Baker BS, Powles AV, Fry L: Psoriasis and streptococci: the natural selection of psoriasis revisited. Br J Dermatol 2009; 160:929-937.
6. Nikaein A, Phillips C, Gilbert SC, Savino D, Silverman A, Stone MJ, et al: Characterization of skin-infiltrating lymphocytes in patients with psoriasis. J Invest Dermatol 1999; 96:3-9.
7. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG: The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113:752-759.
8. Krueger GG: Current concepts and review of alefacept in the treatment of psoriasis. Dermatol Clin 2004; 22:407-426.
9. Lebwohl M, Tyring SK, Hamilton TK, et al: A novel targeted T-cell modulator, efaluzimab, for plaque psoriasis. N Engl J Med 2003; 349: 1987-1990.
10. Martin A, Gitierrez E, Muglia, Mc Donald CJ, Guzzo C, Gottlieb A, et al: A mulitcenter dose-escalation trial with denileukin diftitox (DAB389IL-2) in patients with severe psoriasis. J Am Acad Dermatol 2001; 45:871-881.
11. Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW, Crosby D, et al: Administration of DAB389IL-2 to patients with reca lcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol 1998; 38: 938-944.
12. Graves JE, Nunley K, Heffernan MP: Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (par t 2 of 2). J Am Acad Dermatol 2007; 56: 55-79.
13. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al: Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 cells. J Invest Dermatol 2008; 128:1208-1211.
14. Haider AS, Lowes MA, Suarez-Farinas M, Zaba LC, Cardinale I, Khatcherian A, et al: Identif ication of cel lu lar pat hways of 'type 1' Th17 T cells and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through phar-macogenomic study of cyclosporine A in psoriasis. J Immunol 2008; 180: 1913-1920.
15. Subramaniam SV, Cooper RS, Adunyah SE: Evidence for the involvement of JAK/STAT pathway in the signaling mechanism of in-terleukin-17. Biochem Biophys Res Commun 1999; 262: 14.
16. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suarez-farinas M, et al: Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204:3183-3194.
17. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al: PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665-1674. (Pubitemid 351671883)
18. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al: Efficacy and safety of ustekinumab, a human interleukin-12.23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675-1684.
19. Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A: Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 274-285.
20. Wang H, Grzywacz B, Sukovich D, McCullar V, Cao Q, Lee AB, Blazar BR, Cornfield DN, Miller JS, Verneris MR: The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood 2007; 110: 1530-1539.
21. Kaminuma O: Selective inhibitors of nuclear factor of activated T cells: potential therapeutic drugs for the treatment of immunological and inflammatory diseases. Inflamm Allergy Drug Targets 2008; 7: 35-40.
22. Bos JD, de Rie MA, Teunissen MB, Piskin G: Psoriasis: dysregulation of innate immunity. Br J Dermatol 2005; 152:1098-1107.
23. Cumberbatch M, Singh M, Dearman RJ, Young HS, Kimber I, Griffiths CE: Impaired Langerhans cell migration in psoriasis. J Exp Med 2006; 203: 953-956.
24. Wang H, Peters T, Sindrilaru A, Scharffetter-Kochanek K: Key role of macrophages in the pathogenesis of CD18 hypomorphic murine model of psoriasis. J Invest Dermatol 2009; 129:1100-1114.
25. Seung NR, Park EJ, Kim CW, Kim KH, Kim KJ, Cho HJ, Park HR: Comparison of expression of heat-shock protein 60, Toll-like receptors 2 and 4, and T-cell receptor gamma-delta in plaque and guttate psoriasis. J Cutan Pathol 2007; 34: 903-911.
26. de Jongh GJ, Zeeuwen PL, Kucharekova M, Pfundt R, van der Valk PG, Blokx W, Dogan A, Hiemstra PS, van de Kerkhof PC, Schalkwijk J: High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol 2005; 125: 1163-1173.
27. Janeway C, Travers P, Walport M, Shlomchik M: Immunobiology: The Immune System in Health and Disease, ed 6. New York, Garland Science, 2004.
28. Brilot F, Strowig T, Munz C: NK cells interactions with dendritic cells shape innate and adaptive immunity. Front Biosci 2008; 13: 6443-6454.
29. Marshall JD, Heeke DS, Abbate C, Yee P, Van Nest G: Induction of interferon-γ from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-α and tumour necrosis factor-α. Immunology 2006; 117:38-46.
30. Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, Kiessling R, Jörnvall H, Wigzell H, Gudmundsson GH: The human antimicrobial and chemotactic peptides LL-37 and a-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2001; 96:3086-3093.
31. Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L, et al: Induction of IL-17+ T cell trafficking and development by IFN-γ: mechanism and pathological relevance in psoriasis. J Immunol 2008; 181: 4733-4741.
32. Seaman WE: Natural killer and natural killer T cells. Arthritis Rheum 2000; 95:S14-S18.
33. Elewaut D, Kronenberg M: Molecular biology of NK-T cell specificity and development. Semin Immunol 2000; 12: 561-568.
34. Bonish B, Jullien D, Dutronc Y, Huang BB, Modlin R Spada FM, Porcelli SA, Nickoloff BJ: Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol 2000; 165:4076-4085.
35. Kirby B, Al-Jiffri O, Cooper RJ, Corbitt G, Klapper PE, Griffiths CE: Investigation of cytomegalovirus and human herpes viruses 6 and 7 as possible causative antigens in psoriasis. Acta Derm Venereol 2000; 80:404-406.
36. Farkas A, Tonel G, Nestle FO: Interferon-α and viral triggers promote functional maturation of human monocyte-derived dendritic cells. Br J Dermatol 2008; 158:921-929.
37. Cameron AL, Kirby B, Griffiths CEM: Natural killer cells and natural killer T cells in psoriasis. Arch Dermatol Res 2002; 294:363-369.
38. Vissers WH, Arndtz CH, Muys L, Van Erp PE, de Jong EM, van de Kerkhof PC: Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors which appear late. Br J Dermatol 2004; 150: 852-859.
39. -NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol 2006; 36: 118-128.
40. Liao YH, Jee SH, Sheu BC, Huang YL, Tseng MP, Hsu SM, Tsai TF: Increased expression of the natural killer cell inhibitory receptor CD94/NKG2A and CD158b on circulating and lesional T cells in patients with chronic plaque psoriasis. Br J Dermatol 2006; 155: 318-324.
41. Majewski S, Wasik M, Jabłońska S, Kamiński M, Fraczykowska M: Defective natural-killer- and killer-cell activity associated with increased polymorphonuclear leukocyte adherence in psoriasis. Arch Dermatol Res 1986; 278: 264-269.
42. Cameron AL, Kirby B, Griffiths CEM: Circulating natural killer cells in psoriasis. Br J Dermatol 2003; 149:160-164.
43. Koreck A, Surányi A, Szöny BJ, Farkas A, Bata- Csörgö Z, Kemény L, Dobozy A: CD3+CD56+ NK T cells are significantly decreased in the peripheral blood of patients with psoriasis. Clin Exp Immunol 2002; 127: 176-182.
44. van der Vliet H J, von Blomberg BM, Nishi N, Reijm M, Voskuyl AE, van Bodegraven AA, Polman CH, Rustemeyer T, Lips P, van den Eertwegh AJ, Giaccone G, Scheper RJ, Pinedo HM: Circulating V(α24+) Vβ11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001; 100:144-148.
45. Yanagihara Y, Shiozawa K, Takai M, Kyogoku M, Shiozawa S: Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA). Clin Exp Immunol 1999; 118: 131-136.
46. Sumida T, Sakamoto A, Murata H, Makino Y, Takahashi H, Yoshida S, Nishioka K, Iwamoto I, Taniguchi M: Selective reduction of T cells bearing invariant V α 24J α Q antigen receptor in patients with systemic sclerosis. J Exp Med 1995; 182: 1163-1168.
47. Mieza MA, Itoh JQ, Cui Y, Makino Y, Kawano T, Tsuchida K, et al: Selective reduction of V α 14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol 1996; 156: 4035-4040.
48. Hammond KJ, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, Baxter AG: Alpha/beta-T cell receptor (TCR)+CD4-CD8-(NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 1998; 187: 1047-1056.
49. Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, Porcelli S, Schatz DA, Atkinson MA, Balk SP, Strominger JL, Hafler DA: Extreme Th1 bias of invariant Vα" 24JaQ T cells in type 1 diabetes. Nature 1998; 391: 177-181.
50. Falcone M, Yeung B, Tucker L, Rodriguez E, Sarvetnick N: A defect in interleukin 12-in-duced activation and interferon 7 secretion of peripheral natural killer T cells in non-obese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus. J Exp Med 1999; 190: 963-972.
51. Gardiner CM: Killer cell immunoglobulin-like receptors on NK cells: the how, where and why. Int J Immunogenet 2008; 35: 1-8.
52. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, et al; Collaborative Association Study of Psoriasis: Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat Genet 2009; 41: 199-204.
53. Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, Strange A, Capon F, Spencer CC, et al: A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA- C and ERAP1. Nat Genet 2010; 42:985-990.
54. Suzuki Y, Hamamoto Y, Ogasawara Y, Ishikawa K, Yoshikawa Y, Sasazuki T, Muto M: Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. J Invest Dermatol 2004; 122:1133-1136. (Pubitemid 38651087)
55. Luszczek W, Mańczak M, Cisło M, Nockowski P, Wiśniewski A, Jasek M, et al: Gene for the activating natural killer cell receptor, K IR 2DS1, is associated w it h susceptibilit y to psoriasis vulgaris. Hum Immunol 2004; 65: 758-766.
56. Chang YT, Chou CT, Shiao YM, Lin MW, Yu CW, et al: The killer cell immunoglobulin-like receptor genes do not confer susceptibility to psoriasis vulgaris independently in Chinese. J Invest Dermatol 2006; 126: 2335-2338.
57. Jobim M, Jobim LF, Salim PH, Cestari TF, Toresan R, Gil BC, Jobim MR, Wilson TJ, Kruger M, Schlottfeldt J, Schwartsmann G: A study of the killer cell immunoglobulin-like receptor gene KIR2DS1 in a Caucasoid Brazilian population with psoriasis vulgaris. Tissue Antigens 2008; 72: 392-396.
58. Martin MP, Nelson G, Lee JH, Pellett F, Gao X, Wade J, et al: Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002; 15: 2818.
59. Williams F, Meenagh A, Sleator C, Cook D, Fernandez-Vina M, Bowcock AM, Middleton D: Activating killer cell immunoglobulin-like receptor gene KIR2DS1 is associated with psoriatic arthritis. Hum Immunol 2005; 66: 836-841.
60. Nickoloff BJ, Wrone-Smith T, Bonish B, Porcelli SA: Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161. Arch Dermatol 1999; 135:546-552.
61. Nickoloff BJ, Wrone-Smith T: Injection of pre-psoriatic skin with CD4+ Tcells induces psoriasis. Am J Pathol 1999; 155:145-158.
62. Gilhar A, Ullmann Y, Kerner H, Assy B, Shalaginov R, Serafimovich S, et al: Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors. J Invest Dermatol 2002; 119:384-391.
63. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO: Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-α. J Exp Med 2004; 199: 731-736.
64. Curry JL, Qin JZ, Robinson J, Nickoloff BJ: Reactivity of resident immunocytes in normal and prepsoriatic skin using an ex vivo skin-explant model system. Arch Pathol Lab Med 2003; 127:289-296.
65. Stratis A, Pasparakis M, Rupec RA, Markur D, Hartmann K, Scharffetter-Kochanek K, et al: Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest 2006; 116:2094-2104.
66. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, Bossuyt PM, Bos JD, de Rie MA: Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-665.
67. Flytström I, Stenberg B, Svensson A, Bergbrant IM: Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158:116-121.
68. Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W: Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-526.
69. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE: An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Alefacept Clinical Study Group. Arch Dermatol 2003; 139: 719-727.
70. Son SW, Kim EO, Ryu ES, et al: Upregulation of Fas and downregulation of CD94/NKG2A inhibitory receptors on circulating natural killer cells in patients with new-onset psoriasis. Br J Dermatol 2009; 161: 281-288.
71. Zhao Y, Fishelevich R, Petrali JP, Zheng L, Anatolievna MA, Deng A, Eckert RL, Gaspari AA: Activation of keratinocyte protein kinase C ζ in psoriasis plaques. J Invest Dermatol 2008; 128:2190-2197.